- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00808769
Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression
May 7, 2015 updated by: Procter and Gamble
The purpose of this study is to compare Prilosec OTC® and Zegerid® in their effects on gastric acid suppression.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Normal subjects who are 18-65 years of age;
- Non-childbearing potential females or those using birth control
Exclusion Criteria:
- History of significant GI disease
- Any significant medical illness
- History of hypersensitivity, allergy or intolerance to omeprazole or other proton pump inhibitors;
- Currently using GI medications
- GI disorder or surgery leading to impaired drug absorption
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Zegerid®
|
capsule(20 mg omeprazole/sodium bicarbonate), single dose
|
Experimental: 2
Prilosec OTC®
|
Omeprazole-magnesium 20.6 mg, tablet, single dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Mean Percent Time Gastric pH > 4.0 on Day 1
Time Frame: continuously over a 24 hour period
|
In this study, there was evidence of gastric pH probe failure and a high incidence of biologically improbable pH measurements (sustained pH < 1.0) that bring the validity of the results into question.
The results of this study are, therefore, inconclusive.
|
continuously over a 24 hour period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: John McRorie, PhD, FACG, AGAF, Procter and Gamble
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2008
Primary Completion (Actual)
December 1, 2008
Study Completion (Actual)
December 1, 2008
Study Registration Dates
First Submitted
December 15, 2008
First Submitted That Met QC Criteria
December 15, 2008
First Posted (Estimate)
December 16, 2008
Study Record Updates
Last Update Posted (Estimate)
June 1, 2015
Last Update Submitted That Met QC Criteria
May 7, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2008122
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Normal Healthy Subject Population
-
University of RochesterCompleted
-
Nervive, Inc.Centro Nacional de Investigacion en Imagenologia e Instrumentacion Medica...Completed
-
Cyberonics, Inc.CompletedECG Comparisons in Normal Healthy SubjectUnited States
-
Fundación Pública Andaluza para la Investigación...Completed
-
Samuel FortinCompleted
-
Changchun GeneScience Pharmaceutical Co., Ltd.Completed
-
CelltrionCompletedHealthy SubjectKorea, Republic of
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
Staidson (Beijing) Biopharmaceuticals Co., LtdCompleted
-
GeneScience Pharmaceuticals Co., Ltd.Completed
Clinical Trials on Zegerid®
-
BayerCompleted
-
NorgineCompletedGastroesophageal RefluxPoland
-
NorgineCompletedAcid Reflux | Gastro Oesophageal Reflux DiseaseUnited Kingdom
-
Yvonne RomeroBausch Health Americas, Inc.CompletedErosive EsophagitisUnited States
-
BayerCompleted
-
BayerBausch Health Americas, Inc.CompletedGastric Acid | Human Experimentation
-
BayerCompleted
-
Stanford UniversityTerminatedGastroesophageal Reflux | Barrett EsophagusUnited States
-
University of Missouri-ColumbiaCompleted